De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression

Igawa, Takuro; Sato, Yasuharu; Takata, Katsuyoshi; Iwaki, Noriko; Tanaka, Takehiro; Asano, Naoki; Maeda, Yoshinobu; Orita, Yorihisa; Nakamura, Naoya; Nakamura, Shigeo; Yoshino, Tadashi

doi:10.1186/1746-1596-8-81

Cited by 11 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overexpression of cyclin D2 was also found to be associated with CD5 positivity in DLBCL, especially in de novo cases (24). In our cohort, the low number of cyclin D2-positive cases also did not allow statistical analysis.…”

Section: Discussioncontrasting

confidence: 57%

“…Expression of cyclin D2 has been also repeatedly studied in DLBCL. The fraction of cyclin D2-positive cases varies between 13 and 62% and this feature was shown to be an independent indicator of poor survival (18,(22)(23)(24). Cyclin D2 overexpression is closely associated with CD5-positive cases de novo (24).…”

Section: Introductionmentioning

confidence: 99%

“…The fraction of cyclin D2-positive cases varies between 13 and 62% and this feature was shown to be an independent indicator of poor survival (18,(22)(23)(24). Cyclin D2 overexpression is closely associated with CD5-positive cases de novo (24). The CD5-positive cases de novo represent a DLBCL subtype predominantly occurring in females and characterized by a higher age at diagnosis and a significantly poorer survival compared to CD5-negative DLBCLs (25).…”

Section: Introductionmentioning

confidence: 99%

“…The CD5-positive cases de novo represent a DLBCL subtype predominantly occurring in females and characterized by a higher age at diagnosis and a significantly poorer survival compared to CD5-negative DLBCLs (25). The frequency of cyclin D3 overexpression in DLBCL cases ranges between 20 and 41% (18,24,26) and seems to be associated with poor response to chemotherapy and shorter overall survival (26).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas

et al. 2016

View full text Add to dashboard Cite

D-type cyclins are involved in cell cycle regulation and play an important role in the pathogenesis of lymphomas. Aberrant expression of cyclin D1 is associated with mantle cell lymphoma (MCL) and serves as a diagnostic marker of MCL. Analysis of cyclin D expression in tumor tissues of patients with diffuse large B-cell lymphoma (DLBCL) which comprises a heterogeneous group of tumors may contribute to their stratification. We analyzed expression of cyclin D1, D2, and D3 mRNAs in 30 MCL and 104 DLBCL patients using qRT-PCR and addressed their significance for disease outcome. We confirmed a high level of cyclin D1 mRNA in 29 MCL cases (97%). One case (3%) was identified as positive for cyclin D2. Expression of cyclin D1 was limited to MCL and did not occur in DLBCL. Overexpression of cyclin D2, which is rare in MCL, occurred more frequently in DLBCL (11 cases, 10.6%). We showed that high expression of cyclin D2 in DLBCL cases de novo decreased the overall survival rate (P=0.016) and progression-free survival (P=0.009). The expression pattern of cyclin D3 was similar in both types of studied lymphomas and it did not affect the disease outcome.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although there is no cytomorphologic difference between CD5 þ and CD5 À DLBCL NOS, cyclin D2 has been reported to be highly specific for de novo CD5 þ DLBCL. 30 For practical diagnostics, the pleomorphic variant of MCL and the DLBCL variant of the Richter transformation from CLL/SLL should be ruled out in CD5 þ B-cell lymphomas with medium to large cell sizes. The CD5…”

Section: 21mentioning

confidence: 99%

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang

Zu²

2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity.Objectives.-To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells.Data Sources.-Published and PubMed-indexed English literature was reviewed.Conclusions.-Although the presence or absence of CD5 and CD10 expression should be included in the initial immunohistochemistry screening panel for mature B-cell lymphomas, appropriate and judicial use of other B-cell antigens is necessary to ensure correct diagnoses. Furthermore, although the status of CD5 and CD10 expression is associated with certain prototypes of B-cell lymphomas, their expression is not specific. Plasma cells from plasma cell neoplasias and B-cell lymphomas exhibit overlapping but relatively distinct immunophenotypes; thus, a panel of immunohistochemical markers (CD19, CD45, CD56, and CD117) can be employed for their proper identification. Lastly, CD138 staining results are almost always positive in a group of aggressive B-cell lymphomas with plasmablastic features, including plasmablastic plasma cell myeloma, plasmablastic lymphoma, and ALK-1 þ large B-cell lymphoma.

show abstract

De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances

Wen-jie

2020

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Despite its low frequency in all variants of diffuse large B-cell lymphoma (DLBCL), CD5 þ DLBCL has gradually gained the attention it deserves, the result of its poorer outcomes compared to DLBCL without the CD5 signature. CD5 þ DLBCL is classified as activated B-cellelike (ABC)/nonegerminal-center B-cellelike (GCB) DLBCL with elusive genetic features, and patients are frequently characterized as being older and female, and as having Eastern Cooperative Oncology Group performance status > 1, high International Prognostic Index score, tendency to develop B symptoms, and advanced-stage disease with high central nervous system relapse and bone marrow involvement rate. The mechanism underlying the poor prognosis in CD5 þ DLBCL has not been fully explored, and we summarize the reported potential mechanisms, including CD5-mediated B-cell receptor (BCR)-dependent and -independent pathways. The former involves the inhibition of BCR signaling, and the latter involves the BCR-independent overexpression of interleukin 10, Bcl-2 (antiapoptotic B-cell leukemia/lymphoma 2), cyclin D2, and CXCR4 (C-X-C motif chemokine receptor 4). The efficacy of traditional regimen R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is currently not satisfied in CD5 þ DLBCL. Therapies of larger doses, such as R-DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab), R-ACVBP (rituximab plus doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone), R-DA-EPOCH plus central nervous system prophylaxis, can improve the overall survival in CD5 þ DLBCL patients, while allogeneic hematopoietic stem-cell transplantation still remains controversial as a salvage treatment. In addition, some novel drugs, such as lenalidomide, CXCR4 antagonists, Bruton tyrosine kinase inhibitors, Bcl-2 inhibitors, and immunotherapy, have been reported to have encouraging results and may improve the outcomes of these patients. In the present review, we comprehensively summarize the biology, mechanism, and treatment of CD5 þ DLBCL.

show abstract

De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression

Cited by 11 publications

References 14 publications

Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas

Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances

Contact Info

Product

Resources

About